Outcomes of Primary Vitrectomy for Rhegmatogenous Retinal Detachment With No Postoperative Positioning
- PMID: 38770069
- PMCID: PMC11102711
- DOI: 10.1177/24741264241237022
Outcomes of Primary Vitrectomy for Rhegmatogenous Retinal Detachment With No Postoperative Positioning
Abstract
Purpose: To evaluate the anatomic and visual outcomes of primary vitrectomy for rhegmatogenous retinal detachment (RRD) repair using no amount of postoperative prone positioning to clarify the role of face-down posturing for RRD reattachment. Methods: This retrospective consecutive interventional case series comprised patients who had primary vitrectomy for RRD repair. The surgical outcomes, single-surgery anatomic success rate, and postoperative best-corrected visual acuity (BCVA) were assessed. The primary objective was to evaluate the anatomic and visual outcomes of vitrectomy RRD reattachment using no postoperative prone positioning. Results: This study comprised 116 eyes of 116 patients. Single-surgery anatomic success was achieved in 112 (96.5%) of 116 eyes. The single-surgery anatomic success rate was 100% in phakic patients (n = 56) and 93% in pseudophakic patients (n = 60), with both groups having an improvement in the mean BCVA. Conclusions: Primary vitrectomy with no postoperative prone positioning is a successful surgical intervention for RRD repair. The anatomic closure rate in this study is one of the highest reported in the literature and involved a large number of macula-off RRDs, with minimal complications and a significant improvement in BCVA, primarily using 14% perfluoropropane for gas tamponade.
Keywords: postoperative positioning; retinal detachment; vitrectomy.
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Almeida: Acelyrin, Alcon, Alimera Sciences, Allergan/Abbvie, Bausch + Lomb, Bayer, Boehringer Ingelheim, Citrus Therapeutics, Clinical Trials Network, EyePoint Pharmaceuticals, Inc, Genentech, Gyroscope Therapeutics, Novartos, Ocugen, Opthea, Regeneron, RegenXBio, Roche, Samsara Vision, Spherix Consulting Group. Dr. Chin: Alimera Sciences, Allergan, Bayer, Citrus Therapeutics, Genentech, Hexal AG/Sandoz Inc, Iveric Bio, Kodiak Sciences, Novartis, Opthea, Regeneron. None of the other author(s) declared potential conflicts of interest with respect to the research, authorship, and/or publication of the article.
References
-
- Johnson MT. Postoperative positioning following RD surgery. Retinal Physician. 2013;10:25-29. Accessed November 18, 2022. https://www.retinalphysician.com/issues/2013/july-aug/postoperative-posi...
LinkOut - more resources
Full Text Sources
